Immunopathogenesis of Ulcerative Colitis and Crohn’s Disease
Abstract
Crohn’s disease and ulcerative colitis are two forms of inflammatory bowel disease, caused by an altered mucosal immune response, and characterized by chronic inflammation of the gastrointestinal tract, augmentation of pro-inflammatory mediator production, and reduction of those with anti-inflammatory effects, as well as by upregulation of the expression of chemokines and adhesion molecules, thus promoting cell infiltration into the inflamed tissue, which finally leads to epithelial cell apoptosis and mucosal damage.
How to cite this article:
Bribi N, Yanat B, Ouahmed-Boudaoud H. Immunopathogenesis of Ulcerative Colitis and Crohn’s Disease. Int J Adv Res MicroBiol Immunol 2019; 1(1): 45-48.
References
Pastorelli L, De Salvo C, Mercado JR et al. Central role of the gut epithelial barrier in the pathogenesis of chronic intestinal inflammation: lessons learned from animal models and human genetics. Front Immunol 2013; 17: 1-22.
Asakura H, Kitahora T. Chapter 3: Antioxidants in Inflammatory Bowel Disease, Ulcerative Colitis, and Crohn Disease. In: Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease. 2013; 37-53.
Goll R, Granlund AVB. Intestinal barrier homeostasis in inflammatory bowel disease. Scand J Gastroent 2015; 50(1): 3-12.
Dothel G, Vasina V, Barbara G et al. Animal models of chemically induced intestinal inflammation: Predictivity
and ethical issues. Pharmacol Ther 2013; 139(1): 71-86.
Baumgart DC, Carding SR. Gastroenterology 1: Inflammatory bowel disease: cause and immunobiology.
Lancet 2007; 12(369): 1627-1640.
Karlinger K, Gyorke T, Mako E et al. The epidemiologyand the pathogenesis of inflammatory bowel disease.
Eur J Radiol 2000; 35(3): 154-167.
Wallace KL, Zheng LB, Kanazawa Y et al. Immunopathology of inflammatory bowel disease. World J Gastroenterol 2014; 20(1): 6-21.
Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun Rev 2004; 3(5): 394-400.
Neuman MG. Signaling for inflammation and repair in inflammatory bowel disease. Rom J Gastroent 2004; 13(4): 309-316.
Triantafillidis J, Merikas E, Georgopoulos F. Current and emerging drugs for the treatment of inflammatory bowel disease. Drug Des Dev Ther 2011; 185: 185-210.
Neuman MG, Nanau RM. Inflammatory bowel disease: role of diet, microbiota, life style. Tran Res 2012; 160: 29-44.
Ferguson LR, Shelling AN, Browning BL et al. Genes, diet and inflammatory bowel disease. Mutat Res 2007;
: 70-83.
Sanchez B, Ruiz L, Gueimonde M et al. Adaptation of bifidobacteria to the gastrointestinal tract and functional consequences. Pharmacol Res 2013; 69(1): 127-136.
Hyun JG, Mayer L. Mechanisms underlying inflammatory bowel disease. Drug Discovery Today Dis Mech 2006;
(4): 457-462.
Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immuno 2014; 14: 329-342. 16. Bianco AM, Girardelli M, Tommasini A. Genetics of inflammatory bowel disease from multifactorial to monogenic forms. World J Gastroentero 2015; 21: 12296-12310.
Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto-Furusho J. Role of cytokines in inflammatory bowel disease. World J Gastroent 2008; 14: 4280-4288.
Wirtz S, Popp V, Kindermann M et al. Chemically induced mouse models of acute and chronic intestinal inflammation. Nat Protoc 2017; 12(7): 1295-1309.
Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Ann Rev Med 2000; 51: 289-298.
Bribi N, Algieri A, Rodriguez-Nogales A et al. Intestinal anti-inflammatory effects of total alkaloid extract from Fumaria capreolata in the DNBS model of mice colitis and intestinal epithelial CMT93 cells. Phytomed 2016; 23: 901-13.
Yao X, Huang J, Zhong H et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
Pharmacol Ther 2014; 141(2): 125-139.
Downloads
Published
Issue
Section
License
Copyright (c) 2019 International Journal of Advanced Research in Microbiology and Immunology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
We, the undersigned, give an undertaking to the following effect with regard to our article entitled
“_______________________________________________________________________________________________________________________________________________________________________________
________________________________________________________________________________” submitted for publication in (Journal title)________________________________________________ _______________________________________________________Vol.________, Year _________:-
1. The article mentioned above has not been published or submitted to or accepted for publication in any form, in any other journal.
2. We also vouchsafe that the authorship of this article will not be contested by anyone whose name(s) is/are not listed by us here.
3. I/We declare that I/We contributed significantly towards the research study i.e., (a) conception, design and/or analysis and interpretation of data and to (b) drafting the article or revising it critically for important intellectual content and on (c) final approval of the version to be published.
4. I/We hereby acknowledge ADRs conflict of interest policy requirement to scrupulously avoid direct and indirect conflicts of interest and, accordingly, hereby agree to promptly inform the editor or editor's designee of any business, commercial, or other proprietary support, relationships, or interests that I/We may have which relate directly or indirectly to the subject of the work.
5. I/We also agree to the authorship of the article in the following sequence:-
Authors' Names (in sequence) Signature of Authors
1. _____________________________________ _____________________________________
2. _____________________________________ _____________________________________
3. _____________________________________ _____________________________________
4. _____________________________________ _____________________________________
5. _____________________________________ _____________________________________
6. _____________________________________ _____________________________________
7. _____________________________________ _____________________________________
8. _____________________________________ _____________________________________
Important
(I). All the authors are required to sign independently in this form in the sequence given above. In case an author has left the institution/ country and whose whereabouts are not known, the senior author may sign on his/ her behalf taking the responsibility.
(ii). No addition/ deletion/ or any change in the sequence of the authorship will be permissible at a later stage, without valid reasons and permission of the Editor.
(iii). If the authorship is contested at any stage, the article will be either returned or will not be
processed for publication till the issue is solved.
